Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 Phase III

被引：0
|
作者：
Hasenburg, A. [1 ]
Harter, P. [2 ]
Park-Simon, T-W. [3 ]
Gropp-Meier, M. [4 ]
Heitz, F. [2 ]
Soergel, P. [5 ]
Ataseven, B. [6 ]
Friedlaender, M. [7 ]
Hilpert, F. [8 ]
Pujade-Lauraine, E. [9 ]
机构：
[1] Univ Ctr Mainz, Dept Gynecol & Obstet, Klin & Poliklin Geburtshilfe & Frauengesundheit, Mainz, Germany
[2] Kliniken Essen Mitte, Gynakol & Gyn Onkol, Essen, Germany
[3] Hannover Med Sch, Klin Frauenheilkunde & Geburtshilfe, Hannover, Germany
[4] Malteserkrankenhaus Bonn, Ravensburg, Germany
[5] Hannover Med Sch, Hannover, Germany
[6] Kliniken Essen Mitte, Klin Senol, Essen, Germany
[7] Prince Wales Hosp, Randwick, NSW, Australia
[8] Univ Klinikum Schleswig Holstein, Klin Gynakol & Geburtshilfe, Kiel, Germany
[9] Univ Paris 05, Paris, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
538
引用
收藏
页码：88 / 89
页数：2
相关论文
共 48 条
  • [21] Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study
    Trillsch, Fabian
    Mahner, Sven
    Ataseven, Beyhan
    Asher, Rebecca
    Aryal, Nanda
    Dubot, Coraline
    Clamp, Andrew
    Penson, Richard T.
    Oza, Amit
    Amit, Amnon
    Huzarski, Tomasz
    Casado, Antonio
    Scambia, Giovanni
    Friedlander, Michael
    Colombo, Nicoletta
    Fujiwara, Keiichi
    Sonke, Gabe S.
    Denys, Hannelore
    Lowe, Elizabeth S.
    Lee, Chee K.
    Pujade-Lauraine, Eric
    GYNECOLOGIC ONCOLOGY, 2022, 165 (01) : 40 - 48
  • [22] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
    Pujade-Lauraine, Eric
    Ledermann, Jonathan A.
    Selle, Frederic
    Gebski, Val
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Poveda, Andres
    Pignata, Sandro
    Friedlander, Michael
    Colombo, Nicoletta
    Harter, Philipp
    Fujiwara, Keiichi
    Ray-Coquard, Isabelle
    Banerjee, Susana
    Liu, Joyce
    Lowe, Elizabeth S.
    Bloomfield, Ralph
    Pautier, Patricia
    LANCET ONCOLOGY, 2017, 18 (09): : 1274 - 1284
  • [23] COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 400 MG CAPSULES BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED NON-GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)
    Sackeyfio, A.
    Gill, J.
    Hettle, R.
    Siddiqui, K.
    Friedlander, M.
    Ledermann, J. A.
    VALUE IN HEALTH, 2017, 20 (09) : A412 - A412
  • [24] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial (vol 15, pg 852, 2014)
    Ledermann, J.
    Harter, P.
    Gourley, C.
    LANCET ONCOLOGY, 2015, 16 (04): : E158 - E158
  • [25] POLO: Efficacy and Health-Related Quality of Life (HRQOL) with Maintenance Olaparib Following First-Line Platinum-Based Chemotherapy (PBC) in Patients (PTS) with a Germline BRCA Mutation and Metastatic Pancreatic Cancer (MPC)
    Reinacher-Schick, Anke C.
    Kindler, Hedy L.
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Mercade, Teresa Macarulla
    Hall, Michael J.
    Park, Joon Oh
    Hochhauser, Daniel
    Oh, Do-Youn
    Tortora, Giampaolo
    Algul, Hana
    O'reilly, Eileen M.
    Mcguinness, David
    Cui, Karen
    Schlienger, Katia
    Locker, Gershon Y.
    Golan, Talia
    Arnold, Dirk
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 68 - 68
  • [26] Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
    Poveda, Andres
    Floquet, Anne
    Ledermann, Jonathan A.
    Asher, Rebecca
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Friedlander, Michael
    Baldoni, Alessandra
    Park-Simon, Tjoung-Won
    Tamura, Kenji
    Sonke, Gabe S.
    Lisyanskaya, Alla
    Kim, Jae-Hoon
    Filho, Elias Abdo
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Rowe, Phil
    Vergote, Ignace
    Pujade-Lauraine, Eric
    LANCET ONCOLOGY, 2021, 22 (05): : 620 - 631
  • [27] Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
    Poveda, Andres
    Floquet, Anne
    Ledermann, Jonathan A.
    Asher, Rebecca
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Friedlander, Michael
    Baldoni, Alessandra
    Park-Simon, Tjoung-Won
    Tamura, Kenji
    Sonke, Gabe S.
    Lisyanskaya, Alla
    Kim, Jae-Hoon
    Filho, Elias Abdo
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Rowe, Phil
    Vergote, Ignace
    Pujade-Lauraine, Eric
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2021, 76 (09) : 535 - 536
  • [28] Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.
    Korach, Jacob
    Turner, Simon
    Milenkova, Tsveta
    Alecu, Iulian
    McMurtry, Emma
    Bloomfield, Ralph
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Maintenance olaparib monotherapy for platinum-sensitive relapsed ovarian cancer in patients without a germline BRCA1/BRCA2 mutation: Secondary safety results from the phase IIIb OPINION study
    Colombo, Nicoletta
    Madry, Radoslaw
    Skof, Erik
    Weberpals, Johanne
    Blakeley, Chris
    Marshall, Helen
    Brickel, Neil
    Poveda, Andres
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S81 - S82
  • [30] Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.
    Tjokrowidjaja, Angelina
    Lee, Chee Khoon
    Friedlander, Michael
    Gebski, Val
    Gladieff, Laurence
    Ledermann, Jonathan A.
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Manso, Luis
    Pisano, Carmela
    Asher, Rebecca
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Fujiwara, Keiichi
    Sonke, Gabe S.
    Vergote, Ignace
    Kim, Jae-Weon
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345